PURPOSE: Perfluorohexyloctane ophthalmic solution (PFHO; MIEBO) is indicated for the treatment of signs and symptoms of dry eye disease (DED). This study evaluated patient perceptions and satisfaction early in treatment with PFHO.

METHODS: This prospective, multicenter, open-label, phase 4 study (NCT06309953) enrolled adults with history of DED for ≥6 months, tear film breakup time (TFBUT) ≤5 sec, Schirmer I test (without anesthesia) score ≥5 mm, Meibomian gland dysfunction (MGD) score ≥3 (range, 0-15), and total corneal fluorescein staining (tCFS) score ≥4 and ≤11 (range, 0-15). PFHO was instilled in both eyes QID for 14 days. Patients completed early outcome surveys on days 1 (baseline), 3, 7, and 14 clinic visits, which assessed DED symptom severity (overall and 8 symptoms) and treatment satisfaction (visual analog scale [0-100]). Primary endpoint was mean change from baseline (CFB) in overall DED symptom severity at Day 7.

RESULTS: 99 patients were enrolled (mean age, 61.3 years; 85.9% females). At baseline, mean scores (both eyes) were: TFBUT, 3.6 sec; Schirmer I test, 14.2 mm; MGD score, 8.3; and tCFS, 5.2. Mean CFB in overall DED symptom severity was statistically significant at Day 7 (baseline: 72.1; Day 7: 27.8; CFB: -44.5 [61.7% reduction]; P<0.0001) and at all follow-up visits p><0.0001). mean cfb was also statistically significant p><0.0001) at all follow-up times for severity of all 8 symptoms eye dryness burning stinging eye itching light sensitivity eye pain eye tiredness eye irritation and blurred vision. median rating of treatment satisfaction was 83.0 at day 3 86.0 at day 7 and 90.0 at day 14.>

CONCLUSIONS: Early in the course of treatment with PFHO, patients with DED experienced significant reductions in dry eye symptoms severity. Treatment satisfaction with PFHO was high.